ABSTRACT
The association between anemia and outcomes in glioblastoma patients is unclear. We analyzed data from 1346 histologically confirmed adult glioblastoma patients in the TriNetX Research Network. Median hemoglobin and hematocrit levels were quantified for 6 months following diagnosis and used to classify patients as anemic or non-anemic. Associations of anemia and iron supplementation of anemic patients with median overall survival (median-OS) were then studied. Among 1346 glioblastoma patients, 35.9% of male and 40.5% of female patients were classified as anemic using hemoglobin-based WHO guidelines. Among males, anemia was associated with reduced median-OS compared to matched non-anemic males using hemoglobin (HR 1.24; 95% CI 1.00-1.53) or hematocrit-based cutoffs (HR 1.28; 95% CI 1.03-1.59). Among females, anemia was not associated with median-OS using hemoglobin (HR 1.00; 95% CI 0.78-1.27) or hematocrit-based cutoffs (HR: 1.10; 95% CI 0.85-1.41). Iron supplementation of anemic females trended toward increased median-OS (HR 0.61; 95% CI 0.32-1.19) although failing to reach statistical significance whereas no significant association was found in anemic males (HR 0.85; 95% CI 0.41-1.75). Functional transferrin-binding assays confirmed sexually dimorphic binding in resected patient samples indicating underlying differences in iron biology. Anemia among glioblastoma patients exhibits a sex-specific association with survival.
Subject(s)
Anemia , Glioblastoma , Adult , Humans , Male , Female , Iron , Glioblastoma/complications , Anemia/complications , Hemoglobins/metabolism , Dietary SupplementsABSTRACT
Development of bioresponsive theranostic nanoparticles to enhance cancer diagnostics and control cancer metastasis is highly desirable. In this study, we developed such a bioresponsive theranostic nanoparticle for synergistic photoimmunotherapy. In particular, these nanoparticles were constructed by embedding indocyanine green (ICG) into Mn2+-doped amorphous calcium carbonate (ACC(Mn)) nanoparticles, followed by loading of the Toll-like-receptor-7 agonist imiquimod (IMQ). The IMQ@ACC(Mn)-ICG/PEG nanoparticles respond to the acidic pH of the tumor microenvironment (TME) and co-deliver ICG and IMQ into the tumor. Selective phototherapy was achieved upon activation using a near-infrared laser. In the presence of IMQ and arising from phototherapeutically treated tumor cells, tumor-associated antigens give rise to a strong antitumor immune response. Reversal of the immunosuppressive TME via H+ scavenging of the tumor through ACC nanoparticles effectively inhibits tumor metastases. Moreover, the combination of ICG and Mn2+ also serves as an advanced contrast agent for cancer multimode imaging. Overall, these bioresponsive nanoparticles provide a promising approach for cancer theranostics with promising potential for future clinical translation.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Antineoplastic Agents/therapeutic use , Calcium Carbonate/therapeutic use , Nanoparticles/therapeutic use , Neoplasms/diagnostic imaging , Neoplasms/therapy , Animals , Calcium Carbonate/chemistry , Cell Line, Tumor , Contrast Media/radiation effects , Contrast Media/therapeutic use , Female , Hydrogen-Ion Concentration , Imiquimod/therapeutic use , Immunotherapy/methods , Indocyanine Green/radiation effects , Indocyanine Green/therapeutic use , Infrared Rays , Manganese/chemistry , Mice, Inbred BALB C , Nanoparticles/chemistry , Photosensitizing Agents/radiation effects , Photosensitizing Agents/therapeutic use , Theranostic Nanomedicine/methods , Tumor Microenvironment/drug effectsABSTRACT
Photoimmunotherapy has attracted much attention recently for the treatment of metastatic tumors. The development of smart nanocomposites for imaging-guided therapies is needed to improve the efficacy of cancer treatment. Herein, a PEGylated nanocomposite was developed for photothermal-immunotherapy. In particular, this nanocomposite was formulated by hybridizing Fe3O4 nanoparticles (FNPs) with reduced-graphene oxide (rGO) through electrostatic interaction, modified by PEG-NH2 on the surface of FNPs/rGO. The FNPs/rGO-PEG nanocomposites are excellent agents for photothermal therapy (PTT) under irradiation by an 805 nm laser. This nanocomposite could promote the activity of the host antitumor immune response efficiently because of the reduction of tumor-associated macrophages by the incorporation of FNPs. In our experiments, we observed FNPs/rGO-PEG based PTT induced immunogenic cell death accompanied by the release of danger-associated molecular patterns. We also found that FNPs/rGO-PEG + laser irradiation of animal tumors could activate dendritic cells (DCs) in tumor draining lymph nodes. In vivo antitumor studies revealed that FNPs/rGO-PEG nanocomposites, when combined with laser irradiation, could result in desirable photothermal effects and destroy primary tumors. Moreover, intratumoral injection of FNPs/rGO-PEG nanocomposites into 4T1 orthotopic mouse breast tumors, in combination with near-infrared laser irradiation, significantly increased the median survival time of tumor-bearing animals. FNPs/rGO-PEG nanocomposites could also be used for magnetic resonance imaging, which may lead to a MRI-guided photothermal-immunotherapy for metastatic cancers. This study could lead to a cancer treatment strategy that combines PTT with immunotherapies using FNPs/rGO-PEG nanocomposites.
Subject(s)
Ferric Compounds/chemistry , Graphite/chemistry , Immunotherapy/methods , Metal Nanoparticles/chemistry , Phototherapy/methods , Polyethylene Glycols/chemistry , Animals , Antineoplastic Agents/pharmacology , Breast Neoplasms/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Combined Modality Therapy , Dendritic Cells/metabolism , Female , Hyperthermia, Induced , Lasers , Mice , Mice, Inbred BALB C , Nanocomposites/chemistry , Neoplasm Transplantation , Static ElectricityABSTRACT
OBJECTIVE: To test in an animal model the hypothesis that recombinant human proteoglycan 4 (rhPRG4; lubricin), a highly O-glycosylated mucin-like glycoprotein, may be a novel surface-active therapeutic for treating bladder permeability with comorbid bowel permeability. Previously we showed that inducing bladder permeability in rats with dilute protamine sulfate (PS) produced colonic permeability and visceral hypersensitivity, suggesting increased bladder permeability could represent an etiologic factor in both interstitial cystitis-bladder pain syndrome and irritable bowel syndrome. METHODS: We used an animal model of catheterized ovariectomized female rats instilled intravesically with 1 mg/mL PS for 10 minutes that after 24 hours were treated with 1.2 mg/mL lubricin or with vehicle alone. After 24 hours the bladder and colon were removed and permeability assessed electrophysiologically with the Ussing chamber to measure the transepithelial electrical resistance. A second set of rats was treated identically, except permeability was assessed on day 3 and on day 5 using contrast-enhanced magnetic resonance imaging with gadolinium diethylenetriamine penta-acetic acid instilled into the bladder. RESULTS: Intravesical lubricin reversed bladder permeability induced by PS and prevented the concomitant increase in permeability induced in the bowel (organ crosstalk). The protective effect was confirmed with magnetic resonance imaging, and because individual rats could be followed over time, the impermeability of the bladder restored by rhPRG4 remained for 5 days. CONCLUSION: These data indicate that instillation of rhPRG4 into a permeable bladder can restore its normally impermeable state, and that the effect lasts for 5 days and also prevents bowel symptoms often comorbid with interstitial cystitis-bladder pain syndrome.
Subject(s)
Colon/metabolism , Cystitis, Interstitial/drug therapy , Irritable Bowel Syndrome/drug therapy , Proteoglycans/therapeutic use , Urinary Bladder/metabolism , Administration, Intravesical , Animals , Colon/diagnostic imaging , Colon/drug effects , Colon/pathology , Cystitis, Interstitial/etiology , Cystitis, Interstitial/pathology , Disease Models, Animal , Drug Evaluation, Preclinical , Female , Humans , Irritable Bowel Syndrome/etiology , Irritable Bowel Syndrome/pathology , Magnetic Resonance Imaging , Permeability/drug effects , Proteoglycans/pharmacology , Rats , Rats, Sprague-Dawley , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , Urinary Bladder/diagnostic imaging , Urinary Bladder/drug effects , Urinary Bladder/pathologyABSTRACT
PURPOSE: To propose an alternative method of thermoacoustic wave generation based on heating of magnetic nanoparticles (MNPs) using alternating magnetic field (AMF). METHODS: The feasibility of thermoacoustic wave generation from MNPs by applying a short-burst of AMF or a frequency-modulated AMF is theoretically analyzed. As the relaxation of MNPs is strongly dependent upon the amplitude and frequency of AMF, either an amplitude modulated, fixed frequency AMF (termed time-domain AMF) or a frequency modulated, constant amplitude AMF (termed frequency-domain AMF) will result in time-varying heat dissipation from MNPs, which has the potential to generate thermoacoustic waves. Following Rosensweig's model of specific power loss of MNPs in a steady-state AMF, the time-resolved heat dissipations of MNPs of superparamagnetic size when exposed to a short bursting of AMF and∕or to a linearly frequency chirped AMF are derived, and the resulted acoustic propagation is presented. Based on experimentally measured temperature-rise characteristics of a superparamagnetic iron-oxide nanoparticle (SPION) matrix in a steady-state AMF of various frequencies, the heat dissipations of the SPION under time-domain and frequency-domain AMF configurations that could have practical utility for thermoacoustic wave generation are estimated. RESULTS: The initial rates of the temperature-rise of the SPION matrix were measured at an iron-weight concentration of 0.8 mg∕ml and an AMF frequency of 88.8 kHz to 1.105 MHz. The measured initial rates of temperature-rise were modeled by Rosensweig's theory, and projected to 10 MHz AMF frequency, at which a 1 µs bursting corresponding to a 1.55 mm axial resolution of acoustic detection could contain 10 complete cycles of AMF oscillation and the power dissipation is approximately 84 times of that at 1 MHz. Exposing the SPION matrix to a 1 µs bursting of AMF at 10 MHz frequency and 100 Oe field intensity would produce a volumetric heat dissipation of 7.7 µJ∕cm(3) over the microsecond duration of the AMF burst. If the SPION matrix is exposed to a 1 ms long AMF train at 100 Oe field intensity that chirps linearly from 1 to 10 MHz, the volumetric heat dissipation produced over each 2π phase change of the AMF oscillation is estimated to increase from 0.15 to 1.1 µJ∕cm(3) within the millisecond duration of the chirping of AMF. CONCLUSIONS: The heat dissipations upon SPION (â¼1 mg∕ml iron-weight concentration) by a 1 µs bursting of 100 Oe AMF at 10 MHz and a 1 ms train of 100 Oe AMF that chirps linearly from 1 to 10 MHz were estimated to determine the potential of thermal-acoustic wave generation. Although thermoacoustic wave generation from MNPs by time- or frequency-domain AMF applications is predicted, the experimental generation of such a wave remains challenging.
Subject(s)
Hyperthermia, Induced/methods , Magnetite Nanoparticles/chemistry , Magnetite Nanoparticles/radiation effects , Models, Chemical , Computer Simulation , Feasibility Studies , Magnetic Fields , Radiation Dosage , SoundABSTRACT
Laser immunotherapy (LIT) uses a synergistic approach to treat cancer systemically through local laser irradiation and immunological stimulation. Currently, LIT utilizes dye-assisted noninvasive laser irradiation to achieve selective photothermal interaction. However, LIT faces difficulties treating deeper tumors or tumors with heavily pigmented overlying skin. To circumvent these barriers, we use interstitial laser irradiation to induce the desired photothermal effects. The purpose of this study is to analyze the thermal effects of interstitial irradiation using proton resonance frequency (PRF). An 805-nm near-infrared laser with an interstitial cylindrical diffuser was used to treat rat mammary tumors. Different power settings (1.0, 1.25, and 1.5 W) were applied with an irradiation duration of 10 min. The temperature distributions of the treated tumors were measured by a 7 T magnetic resonance imager using PRF. We found that temperature distributions in tissue depended on both laser power and time settings, and that variance in tissue composition has a major influence in temperature elevation. The temperature elevations measured during interstitial laser irradiation by PRF and thermocouple were consistent, with some variations due to tissue composition and the positioning of the thermocouple's needle probes. Our results indicated that, for a tissue irradiation of 10 min, the elevation of rat tumor temperature ranged from 8 to 11°C for 1 W and 8 to 15°C for 1.5 W. This is the first time a 7 T magnetic resonance imager has been used to monitor interstitial laser irradiation via PRF. Our work provides a basic understanding of the photothermal interaction needed to control the thermal damage inside a tumor using interstitial laser treatment. Our work may lead to an optimal protocol for future cancer treatment using interstitial phototherapy in conjunction with immunotherapy.